分子检测与诊断性肺叶切除术在Bethesda III/IV甲状腺结节中的成本效果分析
本研究采用决策树模型,从支付者角度比较诊断性肺叶切除术(DL)、Afirma基因测序分类器(GSC)和ThyroSeq版本3(TSv3)在40岁女性孤立性2 cm Bethesda III/IV甲状腺结节中的成本效果。结果显示,TSv3每例正确诊断成本为14,277美元,GSC为17,873美元,DL为38,408美元,TSv3在概率敏感性分析中68.5%的情况下为首选策略。
要点
- 在Bethesda III/IV甲状腺结节中,分子检测(GSC或TSv3)的成本效果显著优于诊断性肺叶切除术。
- TSv3相比GSC更具成本效果优势,在多数敏感性分析中保持稳健。
- 若无其他甲状腺切除术指征,应强烈考虑使用分子检测作为辅助手段。
核心结论
- 对于Bethesda III/IV甲状腺结节,两种常用分子检测(GSC和TSv3)的成本效果均显著优于诊断性肺叶切除术,其中TSv3比GSC更可能具有成本效果。
研究设计与样本
- 研究采用决策树模型,从支付者角度分析,基础病例为40岁甲状腺功能正常的女性,伴有孤立性2 cm Bethesda III或IV甲状腺结节。
- 模型假设DL组所有患者均接受肺叶切除术,MT阳性患者也接受手术,MT阴性患者接受20年监测。
- 成本数据来自美国医疗保险和医疗补助服务中心(CMS)数据及现有文献,概率参数来自文献。
主要发现
- 每例正确诊断的成本:TSv3为14,277美元,GSC为17,873美元,DL为38,408美元。
- TSv3相比GSC和DL均为优选策略。
- TSv3与GSC的单因素敏感性分析显示,结果对成本、癌症患病率和监测时长的变化稳健。
- 双因素敏感性分析中,在所有考虑的检测成本下,TSv3均优于GSC。
- 概率敏感性分析中,TSv3在68.5%的情况下为首选管理策略。
关键数值与推荐
- 正确诊断定义为DL后恶性组织学证据或MT阴性后20年结节稳定。
- 成本效果以每例正确诊断的成本表示。
临床怎么用
- 在Bethesda III/IV甲状腺结节的管理中,若无其他甲状腺切除术指征,应强烈考虑使用分子检测(GSC或TSv3)作为辅助手段。
- TSv3相比GSC可能更具成本效果优势,但最终选择需结合当地检测可及性和成本。
局限性
- 研究为假设性建模分析,结果依赖于模型假设和输入参数。
- 成本数据主要基于美国CMS数据,可能不适用于其他医疗体系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Molecular tests (MT) using gene expression and/or mutational analysis have been developed to reduce the need for diagnostic surgery for indeterminate (Bethesda III/IV) thyroid nodules. Prior cost-effectiveness studies have shown mixed results but none has included the recent and more comprehensive versions of the two commonly utilized MT. The aim of this study is to compare the cost-effectiveness of diagnostic lobectomy (DL), the Afirma Gene Sequencing Classifier (GSC), and ThyroSeq version 3 (TSv3). Methods: A decision tree from the payer perspective was created using a base case of a 40-year-old euthyroid woman with a solitary 2 cm Bethesda III or IV thyroid nodule. In this model, all patients in the DL arm had lobectomy, which was also performed for patients with positive MT, while those with negative MT underwent 20 years of surveillance. The outcome was a correct diagnosis, defined as malignant histology after DL or 20 years of nodule stability after negative MT. Costs were obtained from the Centers for Medicare & Medicaid Services (CMS) data and existing literature, and probabilities were obtained from the literature. Sensitivity analysis was performed for costs, pretest probability of malignancy, and performance parameters. Results: The cost per correct diagnosis was $14,277 for TSv3, $17,873 for GSC, and $38,408 for DL. TSv3 was preferred over both GSC and DL. One-way sensitivity analysis between TSv3 and GSC demonstrated that the results were robust to variations in cost, cancer prevalence, and length of surveillance. In the two-way sensitivity analysis, TSv3 was preferred over GSC at all considered test costs, and in probabilistic sensitivity analysis, TSv3 was the preferred management strategy in 68.5% of cases. Conclusions: In hypothetical modeling to determine whether surgery versus MT is optimal for indeterminate (Bethesda III/IV) nodules, either of the major MT was considerably more cost-effective than DL, although TSv3 was more likely to be cost-effective than GSC. Use of either MT adjunct should be strongly considered in the absence of other indications for thyroidectomy.
引用
- Nicholson KJ, Roberts MS, McCoy KL, et al. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis. Thyroid. 2019. PMID: 31407625. doi:10.1089/thy.2018.0779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。